200 related articles for article (PubMed ID: 36928998)
1. Pretherapy investigations using highly robust visualized biomarkers from CT imaging by multiple machine-learning techniques toward its prognosis prediction for ALK-inhibitor therapy in NSCLC: a feasibility study.
Sun J; Li F; Yang J; Lin C; Zhou X; Liu N; Zhang B; Song G; Wang W; Huang C; Song Z; Shi L
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7341-7353. PubMed ID: 36928998
[TBL] [Abstract][Full Text] [Related]
2. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
[TBL] [Abstract][Full Text] [Related]
3. Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer.
Yang B; Zhou L; Zhong J; Lv T; Li A; Ma L; Zhong J; Yin S; Huang L; Zhou C; Li X; Ge YQ; Tao X; Zhang L; Son Y; Lu G
Respir Res; 2021 Jun; 22(1):189. PubMed ID: 34183009
[TBL] [Abstract][Full Text] [Related]
4. ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization.
Yamamoto S; Korn RL; Oklu R; Migdal C; Gotway MB; Weiss GJ; Iafrate AJ; Kim DW; Kuo MD
Radiology; 2014 Aug; 272(2):568-76. PubMed ID: 24885982
[TBL] [Abstract][Full Text] [Related]
5. A CT-based radiomics model to predict subsequent brain metastasis in patients with ALK-rearranged non-small cell lung cancer undergoing crizotinib treatment.
Jiang Y; Wang Y; Fu S; Chen T; Zhou Y; Zhang X; Chen C; He LN; Du W; Li H; Lin Z; Zhao Y; Yang Y; Zhao H; Fang W; Huang Y; Hong S; Zhang L
Thorac Cancer; 2022 Jun; 13(11):1558-1569. PubMed ID: 35437945
[TBL] [Abstract][Full Text] [Related]
6. Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: A multicenter study from India.
Patel A; Batra U; Prasad KT; Dabkara D; Ghosh J; Sharma M; Singh N; Suresh P; Jain P; Malik PS; Choudhary P; Ganguly S; Khurana S; Ms S; Bothra S; Muthu V; Biswas B
Curr Probl Cancer; 2020 Jun; 44(3):100571. PubMed ID: 32234264
[TBL] [Abstract][Full Text] [Related]
7. The deep learning model combining CT image and clinicopathological information for predicting ALK fusion status and response to ALK-TKI therapy in non-small cell lung cancer patients.
Song Z; Liu T; Shi L; Yu Z; Shen Q; Xu M; Huang Z; Cai Z; Wang W; Xu C; Sun J; Chen M
Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):361-371. PubMed ID: 32794105
[TBL] [Abstract][Full Text] [Related]
8. Assessment of a Radiomic Signature Developed in a General NSCLC Cohort for Predicting Overall Survival of ALK-Positive Patients With Different Treatment Types.
Huang L; Chen J; Hu W; Xu X; Liu D; Wen J; Lu J; Cao J; Zhang J; Gu Y; Wang J; Fan M
Clin Lung Cancer; 2019 Nov; 20(6):e638-e651. PubMed ID: 31375452
[TBL] [Abstract][Full Text] [Related]
9. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
[TBL] [Abstract][Full Text] [Related]
10. Proteasome Inhibition Overcomes ALK-TKI Resistance in
Tanimoto A; Matsumoto S; Takeuchi S; Arai S; Fukuda K; Nishiyama A; Yoh K; Ikeda T; Furuya N; Nishino K; Ohe Y; Goto K; Yano S
Clin Cancer Res; 2021 Mar; 27(5):1410-1420. PubMed ID: 33310890
[TBL] [Abstract][Full Text] [Related]
11. CT-based radiomics signatures can predict the tumor response of non-small cell lung cancer patients treated with first-line chemotherapy and targeted therapy.
Yang F; Zhang J; Zhou L; Xia W; Zhang R; Wei H; Feng J; Zhao X; Jian J; Gao X; Yuan S
Eur Radiol; 2022 Mar; 32(3):1538-1547. PubMed ID: 34564744
[TBL] [Abstract][Full Text] [Related]
12. Association of anaplastic lymphoma kinase variants and alterations with ensartinib response duration in non-small cell lung cancer.
Hou D; Zheng X; Song W; Liu X; Wang S; Zhou L; Tao X; Lv L; Sun Q; Jin Y; Zhang Z; Ding L; Wu N; Zhao S
Thorac Cancer; 2021 Sep; 12(17):2388-2399. PubMed ID: 34288491
[TBL] [Abstract][Full Text] [Related]
13. Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer.
Ock CY; Yoo SH; Keam B; Kim M; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS
Korean J Intern Med; 2019 Sep; 34(5):1116-1124. PubMed ID: 29950554
[TBL] [Abstract][Full Text] [Related]
14. Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.
Zhang L; Jiang T; Li X; Wang Y; Zhao C; Zhao S; Xi L; Zhang S; Liu X; Jia Y; Yang H; Shi J; Su C; Ren S; Zhou C
Cancer; 2017 Aug; 123(15):2927-2935. PubMed ID: 28346673
[TBL] [Abstract][Full Text] [Related]
15. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
16. Effect of alectinib versus crizotinib on progression-free survival, central nervous system efficacy and adverse events in ALK-positive non-small cell lung cancer: a systematic review and meta-analysis.
Yang YL; Xiang ZJ; Yang JH; Wang WJ; Xiang RL
Ann Palliat Med; 2020 Jul; 9(4):1782-1796. PubMed ID: 32527124
[TBL] [Abstract][Full Text] [Related]
17. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
18. A short-term follow-up CT based radiomics approach to predict response to immunotherapy in advanced non-small-cell lung cancer.
Gong J; Bao X; Wang T; Liu J; Peng W; Shi J; Wu F; Gu Y
Oncoimmunology; 2022; 11(1):2028962. PubMed ID: 35096486
[TBL] [Abstract][Full Text] [Related]
19. CT-Based Radiomic Signature as a Prognostic Factor in Stage IV
Li H; Zhang R; Wang S; Fang M; Zhu Y; Hu Z; Dong D; Shi J; Tian J
Front Oncol; 2020; 10():57. PubMed ID: 32133282
[No Abstract] [Full Text] [Related]
20. Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: A Retrospective Analysis.
Asao T; Fujiwara Y; Itahashi K; Kitahara S; Goto Y; Horinouchi H; Kanda S; Nokihara H; Yamamoto N; Takahashi K; Ohe Y
Clin Lung Cancer; 2017 Jul; 18(4):e251-e258. PubMed ID: 28065466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
